RIGLNasdaqPharmaceutical PreparationsFiscal year ends December 31

RIGEL PHARMACEUTICALS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026

$46.72+0.75 (+1.63%)

Close on Oct 19, 2026

Market cap: $914.31M
P/E (TTM): 2.9
Dividend yield: –

RIGEL PHARMACEUTICALS INC income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	294	179	117	120	149	109	59	45	4.48	20	–	–	–	–	–	–	–
Cost of Revenue	20	19	7.11	1.75	1.08	0.90	0.91	0.29	–	–	–	–	–	–	–	–	–
Gross Profit	275	161	110	118	148	108	58	44	–	–	–	–	–	–	–	–	–
Research & Development	33	23	25	60	65	60	53	47	46	63	63	68	75	79	69	64	91
Selling, General & Admin	116	113	106	112	92	77	75	70	38	21	–	–	–	–	–	–	–
General & Administrative	–	–	–	–	–	–	–	–	38	21	18	23	20	23	22	25	21
Advertising Expenses	2.30	2.10	3.10	2.70	2.30	1.70	–	–	–	–	–	–	–	–	–	–	–
Total Costs & Expenses	169	155	137	176	162	138	128	117	84	90	81	99	97	102	91	90	113
Operating Income	125	24	-20	-56	-12	-29	-69	-73	-80	-70	-52	-91	-89	-99	-86	35	-112
Interest Expense	7.32	7.92	6.87	3.71	4.86	1.35	0.34	–	–	–	–	–	–	–	0.03	0.09	0.20
Interest & Investment Income	3.68	2.09	2.27	0.68	0.05	0.58	2.53	2.20	0.89	0.44	0.22	0.24	0.43	0.52	0.42	0.30	0.60
Merger & Restructuring Charges	–	–	–	1.32	3.52	–	–	–	0.32	5.77	–	–	1.68	–	0	0	1.14
Gain (Loss) on Sale of Assets	0	0.08	-0.27	0.14	–	–	–	–	0.73	0.09	0.06	0.10	0.02	0.02	–	–	–
Pretax Income	122	18	-25	-59	-17	-30	-67	–	–	–	–	–	–	–	-86	38	-112
Income Tax Expense	-245	0.88	0	–	0.61	–	–	0	0	0	0	0	0	–	–	–	–
Net Income incl. Noncontrolling Interests	367	17	-25	-59	-18	-30	-67	-70	-78	-69	-51	–	–	–	–	–	–
Net Income	367	17	-25	-59	-18	-30	-67	–	–	–	–	–	–	–	–	–	–
Net Income to Common	367	17	-25	-59	-18	-30	-67	-70	-78	-69	-51	-91	-89	-99	-86	38	-112
EPS (Basic)(per share)	20.40	0.99	-1.44	-3.44	-1.10	-1.80	-4.00	-4.40	-6.20	-7.30	-5.80	-10.40	-10.20	-13.20	-13.60	7.30	-27.30
EPS (Diluted)(per share)	19.48	0.99	-1.44	-3.44	-1.10	-1.80	-4.00	-4.40	-6.20	-7.30	-5.80	-10.40	-10.20	-13.20	-13.60	7.20	-27.30
Shares Outstanding (Basic, Weighted)(shares)	18	18	17	17	17	17	17	16	13	9.44	8.84	8.77	8.73	7.50	6.33	5.21	4.09
Shares Outstanding (Diluted, Weighted)(shares)	19	18	17	17	17	17	17	16	13	9.44	8.84	8.77	8.73	7.50	6.33	5.26	4.09
EBITDA	128	26	-19	-55	-11	-28	-68	-72	-79	-69	-50	-89	-87	-97	-84	37	-111

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 91.4%
Operating margin: 31.5%
Net margin: 116.3%
Return on equity, FY2025: 185.9%

Financial strength

Current ratio: 1.94
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 63.6%

Valuation

P/E ratio: 2.9
Price to sales: 3.30
Price to book: 2.15
Dividend yield: –